How each regulator records it
The three main documents describe the same semaglutide trials in type 2 diabetes but treat appetite very differently, which explains why some people are told it is “not a side effect” and others that it is common.
| Document | Where it appears | Comparator | 0.5 mg | 1 mg |
|---|---|---|---|---|
| Canadian monograph, Table 2: 7 phase 3a trials, 30–52 weeks [3] | Metabolism and nutrition disorders | 2.0% | 6.3% | 7.2% |
| Canadian monograph, Table 2 [3] | Weight decreased (as an adverse reaction) | 0.2% | 0.9% | 1.5% |
| EU summary, section 4.8: 8 phase 3a trials [2] | Decreased appetite; weight decreased | — | Common (1 in 100 to 1 in 10) | Common |
| US label, revised 05/2026 [1] | Not listed in sections 6.1 or 6.2 | — | — | — |
What those percentages capture
A trial adverse-event table counts people who reported reduced appetite to the study team as an unwanted effect. It does not measure how much less everyone ate. So 7.2% is not the share of people who ate less; a modest drop that nobody reported as unwanted would not appear in the table [3].
The Canadian comparator group mixed placebo with other diabetes medicines (exenatide, sitagliptin and insulin glargine), and the rates were adjusted for differences between trials [3]. Even so, decreased appetite was more than three times as frequent on Ozempic® 1 mg as on comparators, and slightly higher on 1 mg than on 0.5 mg.
The EU summary adds two points that matter for appetite. People with low body weight may have more stomach side effects on semaglutide, and nausea, diarrhoea and vomiting were reported mainly in the first months of treatment [2]. The Canadian monograph likewise notes more gastrointestinal events in people with lower body weight [3].
What a semaglutide 1 mg study measured
A randomised, placebo-controlled crossover trial gave 30 adults with obesity weekly semaglutide, increased to 1.0 mg, for 12 weeks [4]. After a standard breakfast, they ate freely at lunch, dinner and snacks. On semaglutide, total intake across those meals was 24% lower than on placebo. People reported less hunger and fewer food cravings, better control of eating and a lower preference for high-fat foods, while nausea ratings were similar to placebo [4]. Resting metabolic rate, adjusted for lean mass, did not change.
The EU summary describes the same pattern in its pharmacology section: energy intake at three consecutive free meals fell by 18% to 35%, with appetite suppressed both before and after eating [2]. These were people with obesity rather than type 2 diabetes, and 12 weeks is short, so they show the mechanism more clearly than they predict any one person’s experience.
The pooled SUSTAIN programme confirms the wider context: gastrointestinal disorders affected 41.9% of people on injected semaglutide versus 22.0% on comparators and were most frequent during dose starts and increases [5].
Why appetite falls on semaglutide
What the label supports: the EU summary explains that semaglutide acts on GLP-1 receptors in the brain as well as the pancreas, lowering appetite and energy intake, and that it also slightly slows stomach emptying in the early phase after a meal [2].
What is reasonable but less certain: nausea or fullness on some days can add to a low appetite, but the 1 mg study suggests appetite falls even when nausea is not worse than on placebo [4].
General background: MedlinePlus notes that low appetite has many causes beyond medicines, including low mood, grief, thyroid and liver problems, and that it can lead to weight loss [6].
When low appetite may have another cause
MedlinePlus lists conditions that can reduce appetite on their own, which is worth remembering if the change seems out of step with your dose or timing [6]:
- Sadness, depression or grief.
- Long-term liver, kidney or lung disease, heart failure, hepatitis or HIV.
- An underactive thyroid, early pregnancy or dementia.
- Other medicines, such as some antibiotics, chemotherapy, codeine or morphine, and alcohol or drug use.
- Cancers of the stomach, pancreas, colon or ovary, especially with weight loss you cannot explain.
Practical points from official sources
The Medication Guide stresses drinking fluids to lower the chance of dehydration, because nausea, vomiting and diarrhoea can cause fluid loss and, in turn, kidney problems [1]. If your appetite is small, fluids are easy to forget.
MedlinePlus suggests keeping a diet history, a record of everything you eat and drink over at least 24 hours, which helps a clinician judge whether you are getting enough [6]. It also says that when a medicine seems to be lowering appetite, the right step is to ask your provider about the dose or the medicine, not to stop it on your own [6]. Our separate guide on eating with a low appetite covers meal structure in more detail.
Ozempic®-specific points
If you also take insulin or a sulfonylurea, the label warns that the risk of low blood sugar rises and that the dose of those medicines may need lowering when Ozempic® starts [1]. Hunger, shakiness, sweating, confusion and a fast heartbeat are among the signs it lists [1]. Eating much less than usual is worth raising with your prescriber in advance. The label escalates from 0.25 mg over at least four weeks per step, and a new dip in appetite after a step is useful information to bring [1].
Ozempic® is a registered trademark of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Sweating, shakiness, confusion, hunger or a fast heartbeat, especially with insulin or a sulfonylurea
Contact: Treat low blood sugar as your care team has shown you, then call your prescriber
Ozempic® Medication Guide [1]
- Severe stomach pain that does not go away, with or without vomiting
Contact: Stop Ozempic® and call your prescriber right away
Ozempic® Medication Guide [1]